1. Home
  2. IQ vs DRTS Comparison

IQ vs DRTS Comparison

Compare IQ & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iQIYI Inc.

IQ

iQIYI Inc.

HOLD

Current Price

$1.15

Market Cap

1.0B

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$12.13

Market Cap

978.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQ
DRTS
Founded
2009
2015
Country
China
Israel
Employees
N/A
121
Industry
Consumer Electronics/Video Chains
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
978.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
IQ
DRTS
Price
$1.15
$12.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$2.91
$8.67
AVG Volume (30 Days)
6.7M
809.9K
Earning Date
05-18-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.28
N/A
Revenue Next Year
$3.54
$699.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$2.87
52 Week High
$2.76
$14.11

Technical Indicators

Market Signals
Indicator
IQ
DRTS
Relative Strength Index (RSI) 59.21 57.59
Support Level $0.99 $6.59
Resistance Level $1.19 $14.11
Average True Range (ATR) 0.06 0.87
MACD 0.02 0.06
Stochastic Oscillator 86.66 57.77

Price Performance

Historical Comparison
IQ
DRTS

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: